LSE - Delayed Quote GBp

AstraZeneca PLC (AZN.L)

10,444.00

+82.00

+(0.79%)

At close: 5:15:00 PM GMT+1

Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics

Get a deeper insight into the potential performance of Astrazeneca (AZN) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks 5 hours ago

AZN
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos

AstraZeneca, Tempus and Pathos will develop an AI-driven foundational model to develop therapeutics in oncology.

Pharmaceutical Technology 7 hours ago

TEM

AZN
Can Biogen Keep the Beat Streak Alive This Earnings Season?

In the first quarter, lower sales of BIIB's multiple sclerosis drugs are likely to have been offset by revenues from new drugs.

Zacks 7 hours ago

BIIB

AZN
AstraZeneca pushes EU to spend more on drugs amid Trump tariffs threat

The head of Britain’s largest drug company has demanded Europe ramp up spending on medicines amid fears over Donald Trump’s tariffs.

The Telegraph yesterday

AZN
Drug firm bosses call for price increases in Europe amid tariff uncertainty

The boss of AstraZeneca said Europe should increase spending on health treatment in line with recent commitments on defence.

PA Media: Money yesterday

AZN
Why Tempus AI Stock Is Skyrocketing Today

Shares of Tempus AI (NASDAQ: TEM) were skyrocketing 16.5% higher as of 10:39 a.m. ET on Wednesday. The big gain came after the healthcare artificial intelligence (AI) company announced a multiyear partnership with AstraZeneca and Pathos AI to build a multimodal foundation model for cancer drug discovery and development. Tempus AI has invested heavily over the last decade to create one of the world's largest libraries of multimodal data that can be used in developing precision medicines.

Motley Fool yesterday

TEM

AZN
Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know

The latest trading day saw Astrazeneca (AZN) settling at $67.87, representing a +1.45% change from its previous close.

Zacks yesterday

AZN
AstraZeneca rejoins leading U.S. drug lobby group after two-year absence

This decision follows the British drugmaker's announcement last year of a $3.5 billion investment in the United States aimed at expanding its research and development (R&D) and manufacturing capabilities by the end of 2026. The company returns to the trade body amid preparations by pharmaceutical companies to address potential tariffs and drug import duties under the administration of President Donald Trump.

Reuters yesterday

AZN
Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial

The trial aims to assess the safety and efficacy of Enhertu, either as a single agent or with pertuzumab, against the THP.

Clinical Trials Arena 2 days ago

4568.T

AZN
Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ...

Discover how Cellectis SA (CLLS) is advancing its CAR T therapies and securing financial stability through strategic partnerships and investments.

GuruFocus.com 2 days ago

CLLS

AZN
AstraZeneca (LSE:AZN) and Daiichi Sankyo's ENHERTU Shows Promising Results in HER2 Breast Cancer Trial

AstraZeneca (LSE:AZN) recently reported a 1.9% decline in its share price over the last week. This movement coincides with the broader market's downturn, which saw a 1.1% drop amid ongoing concerns about international trade, particularly following U.S. tariff policies. Amid these market pressures, the company's collaboration with Daiichi Sankyo was highlighted by the announcement of successful phase 3 trial results for ENHERTU, which positively impacts the oncology sector. Although...

Simply Wall St. 3 days ago

AZN

AZNCF
Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?

AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, are expected to have driven the company's top line.

Zacks 3 days ago

AZN
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) either alone or in combination with pertuzumab versus standard of care THP (a taxane [docetaxel or paclitaxel], trastuzumab, and pertuzumab) as a first-line treatment in patients with HER2-positive metastatic breast cancer. High-level results from a planned interim analysis showed Enhertu pertuzumab combination demonstrated a statistically significant and clinically meaningf

Benzinga 3 days ago

AZN

4568.T
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer

WILMINGTON, Del., April 21, 2025--Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to a taxane, trastuzumab and pertuzumab (THP) as a 1st-line treatment for patients with HER2-positive metastatic breast cancer.

Business Wire 3 days ago

AZN

AZNCF
Six FTSE 100 stock ideas for the second quarter, according to Barclays

While uncertainty remains high amid Trump's tariff blitz, Barclays analysts have highlighted six UK stock ideas for the second quarter.

Yahoo Finance UK 7 days ago

^GSPC

IMBBF

IMBBY
Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth?

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best pharma stocks to buy for long term growth. U.S. Pharma Turns to China for Drug Deals With big American pharmaceutical […]

Insider Monkey 8 days ago

AZN
Tariff wars to hit popular US-made drugs in China, regulator data shows

China announced on Friday that it would raise its levies on imports of U.S. goods to 125%, hitting back at U.S. President Donald Trump's decision to single out the world's second-largest economy for higher duties. The Trump administration is also currently investigating whether imports of pharmaceutical products threaten U.S. national security, which could be a precursor to slapping tariffs on those products. Big pharmaceutical companies including AstraZeneca, Sanofi, GSK and Eli Lilly have at least one U.S. manufacturing site for their drugs sold in China, records from China's National Medical Products Administration showed.

Reuters 9 days ago

LLY

AZN

SNY
Is AstraZeneca (AZN) The Best UK Stock to Buy According to Billionaires?

We recently published a list of 10 Best UK Stocks to Buy According to Billionaires. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against other best UK stocks to invest in. Like most of the world, the United Kingdom is also facing slower economic growth in 2025, […]

Insider Monkey 10 days ago

AZN
Nasdaq Bear Market: 3 Unstoppable Stocks You Can Buy With $300 Right Now

A small amount of money can go a long way when it's invested in industry leaders with well-defined catalysts.

Motley Fool 10 days ago

GOOG

COMP

TTD
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis

AbbVie's, Rinvoq and AstraZeneca's and Novartis are included in this Analyst Blog.

Zacks 10 days ago

NVS

AZN

ABBV

Performance Overview

Return	AZN.L	FTSE 100 (^FTSE)
YTD	-0.21%	+2.87%
1-Year	-7.98%	+4.56%
3-Year	+1.66%	+11.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AstraZeneca PLC (AZN.L)

Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics

AstraZeneca enters $200m AI cancer pact with Tempus and Pathos

Can Biogen Keep the Beat Streak Alive This Earnings Season?

AstraZeneca pushes EU to spend more on drugs amid Trump tariffs threat

Drug firm bosses call for price increases in Europe amid tariff uncertainty

Why Tempus AI Stock Is Skyrocketing Today

Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know

AstraZeneca rejoins leading U.S. drug lobby group after two-year absence

Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial

Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ...

AstraZeneca (LSE:AZN) and Daiichi Sankyo's ENHERTU Shows Promising Results in HER2 Breast Cancer Trial

Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings?

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer

Six FTSE 100 stock ideas for the second quarter, according to Barclays

Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth?

Tariff wars to hit popular US-made drugs in China, regulator data shows

Is AstraZeneca (AZN) The Best UK Stock to Buy According to Billionaires?

Nasdaq Bear Market: 3 Unstoppable Stocks You Can Buy With $300 Right Now

The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis

Performance Overview